STOCK TITAN

Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced it will report third quarter 2022 financial results on Thursday, November 10, 2022 following the close of the U.S. financial markets. Amylyx’ senior management team will host a conference call and audio webcast at 4:30 p.m. ET to discuss the financial results and other company updates.

To access the conference call, please dial (877) 870-4263 (local) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events. The webcast will be archived and available for replay for 90 days following the event.

About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.

Media

Becky Gohsler

Finn Partners

(646) 307-6307

amylyxmediateam@amylyx.com



Investors

Lindsey Allen

Amylyx Pharmaceuticals, Inc.

(857) 320-6244

Investors@amylyx.com

Source: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Inc

NASDAQ:AMLX

AMLX Rankings

AMLX Latest News

AMLX Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link

About AMLX

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.